摘要
慢性髓性白血病(CML)属于多能造血干细胞恶性骨髓增生性疾病,费城(Ph)染色体是CML的细胞遗传学标志,90%以上CML患者骨髓细胞中发现有Ph染色体,经过20年的研究,CML患者的生存愈后得到了显著改善,特别是伊马替尼研制成功给治疗CML带来了很大飞跃。这篇综述总结这些年来CML的治疗进展。
Chronic myelogenous leukemia（CML） is a myeloproliferative disorder of pluripotent hematopoietic stem cells,whose cell genetic marker is Philadelphia（Ph） chromosome. Above 90 percent of patients with CML has this chromsome in their myeloid cell, whose living subsistance and prognosis has been improved greatly through increasing study dunng 20 years, especially the significant achievement from success development of imatimib. This article reviews progresses on the treatment of CML.
出处
《医学综述》
2006年第21期1329-1332,共4页
Medical Recapitulate
关键词
慢性髓性白血病
信号传导抑制剂571
干扰素-Α
造血干细胞移植
Chronic myelogenous leukemia
Signal conduction inhibitor571
Interferon Alafa
Hematopoietic stem cell transplantation
